LOVFF (Cannara Biotech) Total Assets: $133.21 Mil (As of Feb. 2026)


LOVFF Cannara Biotech Inc LOVFF
84 GF Score
Price $1.18
GF Value $1.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cannara Biotech Total Assets?

Cannara Biotech LOVFF -4.84% 84 Total Assets is $133.21 Mil as of Feb. 2026. GuruFocus rates LOVFF with a GF Score™ of 84/100 and a GF Value™ of $1.18 (Fairly Valued). The stock has 4 warning signs investors should review.

Cannara Biotech's Total Assets for the quarter that ended in Feb. 2026 was $133.21 Mil.

During the past 12 months, Cannara Biotech's average Total Assets Growth Rate was 2.30% per year. During the past 3 years, the average Total Assets Growth Rate was 10.80% per year. During the past 5 years, the average Total Assets Growth Rate was 25.10% per year.

During the past 8 years, Cannara Biotech's highest 3-Year average Total Assets Growth Rate was 73.90%. The lowest was 10.80%. And the median was 39.70%.

Total Assets is connected with ROA %. Cannara Biotech's annualized ROA % for the quarter that ended in Feb. 2026 was 3.79%. Total Assets is also linked to Revenue through Asset Turnover. Cannara Biotech's Asset Turnover for the quarter that ended in Feb. 2026 was 0.16.

Cannara Biotech  (OTCPK:LOVFF) Total Assets Explanation

Total Assets is connected with ROA %.

Cannara Biotech's annualized ROA % for the quarter that ended in Feb. 2026 is

ROA %=Net Income (Q: Feb. 2026 )/( (Total Assets (Q: Nov. 2025 )+Total Assets (Q: Feb. 2026 ))/ count )
=4.872/( (123.679+133.212)/ 2 )
=4.872/128.4455
=3.79 %

Note: The Net Income data used here is four times the quarterly (Feb. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cannara Biotech's Asset Turnover for the quarter that ended in Feb. 2026 is

Asset Turnover
=Revenue (Q: Feb. 2026 )/( (Total Assets (Q: Nov. 2025 )+Total Assets (Q: Feb. 2026 ))/ count )
=19.914/( (123.679+133.212)/ 2 )
=19.914/128.4455
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cannara Biotech Total Assets Related Terms

Cannara Biotech Total Assets Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Total Assets Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Assets
Get a 7-Day Free Trial 73.04 97.25 105.00 113.31 122.23

Cannara Biotech Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.88 122.66 122.23 123.68 133.21
LOVFF
84GF Score
Cannara Biotech Inc LOVFF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cannara Biotech's Total Assets for the fiscal year that ended in Aug. 2025 is calculated as

Total Assets=Total Equity (A: Aug. 2025 )+Total Liabilities (A: Aug. 2025 )
=74.089+48.145
=122.23

Cannara Biotech's Total Assets for the quarter that ended in Feb. 2026 is calculated as

Total Assets=Total Equity (Q: Feb. 2026 )+Total Liabilities (Q: Feb. 2026 )
=88.078+45.134
=133.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $133.21 Mil mean?
Cannara Biotech (LOVFF) has a Total Assets of $133.21 Mil as of Feb. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Total Assets too high?
Cannara Biotech's current Total Assets is $133.21 Mil. Overall, Cannara Biotech has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Total Assets compare to ZTS and UTHR?
Cannara Biotech's Total Assets of $133.21 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current Total Assets is $133.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.18, compared to a current price of $1.18 — trading right at its estimated fair value. The current Total Assets is $133.21 Mil. Cannara Biotech's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Total Assets is $133.21 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued. The current stock price of $1.18 is trading 0% below its estimated GF Value™ of $1.18. GuruFocus considers Cannara Biotech to be Fairly Valued.

Key valuation signals for LOVFF:

  • Total Assets: $133.21 Mil
  • GF Value™: $1.18 vs. price of $1.18 (0% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
84GF Score

Get the complete analysis for LOVFF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price
$1.18
GF Value